Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01152398 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
A Phase 1 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01152398 is a Phase 1 study that has completed, run by Bavarian Nordic. The registered enrollment target is 15 participants.
The verdict
NCT01152398, a Phase 1 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The current trial, BNIT-BR-003, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast cancer. The intent of vaccination is to induce a combined antibody and T-cell anti-HER-2 immune response, which is intended to target HER-2-expressing tumor cells, and may induce tumor regression or slow progression of disease.
Interventions
- BIOLOGICAL MVA-BN-HER2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01152398
The ClinicalTrials.gov registry entry for NCT01152398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MVA-BN-HER2 is the first listed.
NCT01152398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01152398 about?
NCT01152398 is a clinical study titled "A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy". The current trial, BNIT-BR-003, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast cancer. The intent of vaccination is to induce a combined antibody and T-cell anti-HER-2 immune response, which is ...
What is the current status of trial NCT01152398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01152398?
The interventions under investigation include: MVA-BN-HER2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01152398?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.